Skip to main content

Advertisement

SpringerLink
Log in

Local treatment in oligometastasis from breast cancer: an overview

  • REVIEW ARTICLE
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Oligometastasic breast cancer (OMBC) consists of breast cancer patient with a limited number of systemic metastases (≤ 5), all of them candidates for local ablative treatment with the intention of achieving long-term control of the metastasis and, eventually, an increase in survival The first consensus for the management of patients with oligometastatic breast cancer (OMBC) was published in 2007, establishing that a more aggressive multidisciplinary strategy is recommended in order to increase the survival while maintaining a good quality of life. The current scientific evidence is based on observational studies, mainly retrospective, systematic reviews and meta-analyses, and only a randomized nonexclusive study of oligometastatic (OM) published. All trials with Stereotactic Body Radiation Therapy (SBRT) in OM cancer have shown excellent tolerance and good local control, although first trials on Lung SBRT did not prove so excellent tolerance and had some deaths due to bronchus irradiation and secondary hemoptysis. There are multiple ongoing studies researching the benefit of SBRT in oligometastatic breast cancer. Despite the lack of impact on survival seen in the NRG BR-002 Trial, SBRT probably allows the delay of the systemic treatment until progression, and so, improves the quality of life of patients. We have to wait for the results of the ongoing and future studies for clarification of the role of local treatment in OMBC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data availability

The authors confirm that the data supporting the findings of this study are available within the article.

References

  1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8–10.

    Article  CAS  PubMed  Google Scholar 

  2. Halsted WS. The results of radical operations for the cure of carcinoma of the breast. Ann Surg. 1907;46:1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Fisher B. Laboratory and clinical research in breast cancer–a personal adventure: the David A Karnovsky memorial lecture. Cancer Res. 1980;40:3863–74.

    CAS  PubMed  Google Scholar 

  4. Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 2003;3:453–8.

    Article  CAS  PubMed  Google Scholar 

  5. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329–60.

    Article  CAS  PubMed  Google Scholar 

  6. Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther. 2020;5(1):28.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Metastatic breast cancer. Recommendations proposal from the European school of oncology (ESO)-MBC task force. Breast. 2007;16(1):9–10.

    Article  Google Scholar 

  8. Jain SK, Dorn PL, Chmura SJ, Weichselbaum RR, Hasan Y. Incidence and implications of oligometastatic breast cancer. J Clin Oncol. 2012;30(15):e11512–e11512.

    Article  Google Scholar 

  9. Nguyen DH, Truong PT, Walter CV, Hayashi E, Christie JL, Chim CA. Limited M1 disease: a significant prognostic factor for stage IV breast cancer. Ann Surg Oncol. 2012;19:3028–34.

    Article  PubMed  Google Scholar 

  10. Dorn PL, Meriwether A, LeMieux M, Weichselbaum RR, Chmura SJ, Hasan Y. Patterns of distant failure and progression in breast cancer: implications for the treatment of oligometastatic disease. Int J Radiat Oncol. 2011;81:643.

    Article  Google Scholar 

  11. Chalkidou A, Macmillan T, Grzeda MT, Peacock J, Summers J, Eddy S, et al. Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study. Lancet Oncol. 2021;22:98–106.

    Article  PubMed  Google Scholar 

  12. Viani GA, Gouveia AG, Louie AV, Korzeniowski M, Pavoni JF, Hamamura AC, et al. Stereotactic body radiotherapy to treat breast cancer oligometastases: a systematic review with meta-analysis. Radiother Oncol. 2021;164:245–50.

    Article  PubMed  Google Scholar 

  13. Chmura SJ, Winter KA, Woodward WA, Woodward WA, Borges VF, Al-Hallaq HA, et al. NRG BR-002. JCO. 2022;40(16_suppl):1007.

    Article  Google Scholar 

  14. Krug D, Vonthein R, Illen A, Denise Olbrich C, Jörg Barkhausen D, Richter J, et al. Metastases-directed radiotherapy in addition to standard systemic therapy in patients with oligometastatic breast cancer: study protocolfor a randomized controlled multi-national and multi-center clinical trial (OLIGOMA). Clin Transl Radiat Oncol. 2021;28:90–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Trial of Superiority of Stereotactic Body Radiation Therapy in patients with breast cancer (STEREO-SEIN). ClinicalTrials.gov Identifier: NCT02089100

  16. Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, et al. Characterisation and classification of oligometastatic disease: a European society for radiotherapy and oncology and European organisation for research and treatment of cancer consensus recommendation. Lancet Oncol. 2020;21:e18-28.

    Article  PubMed  Google Scholar 

  17. deSouza NM, Liu Y, Chiti A, Oprea-Lager D, Gebhart G, Van Beers BE, et al. Strategies and technical challenges for imaging oligometastatic disease: recommendations from the European organisation for research and treatment of cancer imaging group. Eur J Cancer. 2018;91:153–63.

    Article  PubMed  Google Scholar 

  18. Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I, et al. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol. 2020;148:157–66.

    Article  PubMed  Google Scholar 

  19. E2-RADIatE European Platform for Data Collection. https://www.estro.org/Science/E2RADIATE.

  20. Trovo M, Furlan C, Polesel J, Fiorica F, Arcangeli S, Giaj-Levra N, et al. Radical radiation therapy for oligometastatic breast cancer: results of a prospective phase II trial. Radiother Oncol. 2018;126:177–80.

    Article  PubMed  Google Scholar 

  21. Milano MT, Zhang H, Metcalfe SK, Muhs AG, Okunieff P. Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy. Breast Cancer Res Treat. 2009;115:601–8.

    Article  PubMed  Google Scholar 

  22. David S, Tan J, Savas P, Bressel M, Kelly D, Foroudi F, et al. Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: a prospective clinical trial. Breast. 2020;49:55–62.

    Article  PubMed  Google Scholar 

  23. Tan H, Cheung P, Louie AV, Myrehaug S, Niglas M, Atenafu EG, et al. Outcomes of extra-cranial stereotactic body radiotherapy for metastatic breast cancer: treatment indication matters. Radiother Oncol. 2021;161:159–65.

    Article  PubMed  Google Scholar 

  24. Scorsetti M, Franceschini D, De Rose F, Comito T, Villa E, Iftode C, et al. Stereotactic body radiation therapy: a promising chance for oligometastatic breast cancer. Breast. 2016;26:11–7.

    Article  PubMed  Google Scholar 

  25. Weykamp F, Konig L, Seidensaal K, Forster T, Hoegen P, Akbaba S, et al. Extracranial stereotactic body radiotherapy in oligometastatic or oligoprogressive breast cancer. Front Oncol. 2020;10:987.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol. 2020;38:2830–8.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Harrow S, Palma DA, Olson R, et al. Stereotactic radiation for the comprehensive treatment of oligometastases (SABR-COMET): extended long-term outcomes. Int J Radiation Oncol Biol Phys. 2022;114(4):611–6.

    Article  Google Scholar 

  28. Xing D, Siva S, Hanna G. The abscopal effect of stereotactic radiotherapy and immunotherapy: fool’s gold or El dorado? Clin Oncol. 2019;31:432–43.

    Article  CAS  Google Scholar 

  29. Lugade AA, Sorensen E, Gerber SA, Moran JP, Frelinger JG, Lord EM. Radiation-induced IFN-production within the tumor microenvironment influences antitumor immunity. J Immunol. 2008;180:3132–9.

    Article  CAS  PubMed  Google Scholar 

  30. Welsh JW, Chen D, Baas P, Chang JY, Verma V, Comeaux NI, et al. Radiotherapy to augment pembrolizumab responses and outcomes in metastatic non-small cell lung cancer: pooled analysis of two randomized trials. J Clin Oncol. 2020;38:9548.

    Article  Google Scholar 

  31. Formenti SC, Lee P, Adams S, Goldberg JD, Li X, Xie MW, et al. Focal irradiation and systemic TGFβ blockade in metastatic breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2018;24(11):2493–504.

    Article  CAS  Google Scholar 

  32. Harini D, de Silva PS, Petrone P, Neeson M, Tantalo D, Siva S, et al. Identification of peripheral blood biomarkers that predict response to the combination of radiotherapy and anti-PD1 checkpoint blockade in metastatic breast cancer. In Proceedings of the ASI 48th Annual Scientific Meeting of the Australian and New Zealand Society for Immunology, Adelaide, Australia, 8–12 December 2019

  33. Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2:361–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Pitroda SP, Chmura SJ, Weichselbaum RR. Integration of radiotherapy and immunotherapy for treatment of oligometastases. Lancet Oncol. 2019;20:e434–42.

    Article  CAS  PubMed  Google Scholar 

  35. Gutiontov SI, Pitroda SP, Chmura SJ, Arina A, Weichselbaum RR, et al. Cytoreduction and the optimization of immune checkpoint inhibition with radiation therapy. Int J Radiat Oncol Biol Phys. 2020;108:17–26.

    Article  PubMed  Google Scholar 

  36. Mole RH. Whole body irradiation; radiobiology or medicine? Br J Radiol. 1953;26:234–41.

    Article  CAS  PubMed  Google Scholar 

  37. Lussier YA, Xing HR, Salama JK, Khodarev NN, Huang Y, Zhang Q, et al. MicroRNA expression characterizes oligometastasis(es). PLoS ONE. 2011;6(12):e28650. https://doi.org/10.1371/journal.pone.0028650.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Multidisciplinary Breast Cancer Unit, Radiation Oncology Service, University Hospital of Navarre, Pamplona, Spain

    Ana Manterola Burgaleta & Gemma Asín Felipe

  2. Service of Radiotherapy Oncology, University Hospital of Navarre, Pamplona, Spain

    Ana Manterola Burgaleta, Andrea Barco Burguete, Lombardo Rosas Gutiérrez, Erkuden Burillo Nuín, Gemma Asín Felipe & Fernando Arias de la Vega

  3. “Clinical Research Group in Radiation Oncology”, Health Research Institute of Navarra (IdiSNA), Pamplona, Spain

    Fernando Arias de la Vega

Authors
  1. Ana Manterola Burgaleta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrea Barco Burguete
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lombardo Rosas Gutiérrez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Erkuden Burillo Nuín
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gemma Asín Felipe
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fernando Arias de la Vega
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fernando Arias de la Vega.

Ethics declarations

Conflict of interest

No conflicts of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

For this type of study formal consent in nor required.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Burgaleta, A.M., Burguete, A.B., Gutiérrez, L.R. et al. Local treatment in oligometastasis from breast cancer: an overview. Clin Transl Oncol 25, 2861–2867 (2023). https://doi.org/10.1007/s12094-023-03170-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-023-03170-0

Keywords

Search

Navigation